Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-183.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.65 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -100.30% |
| Return on Assets (Trailing 12 Months) | -69.22% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.69 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.15 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.71 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.80 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.49 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 99.70M |
| Free Float | 97.31M |
| Market Capitalization | $2.41B |
| Average Volume (Last 20 Days) | 1.53M |
| Beta (Past 60 Months) | 2.37 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 27.91% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |